Pronunciation: DAL-te-PAR-in SOE-dee-um
Class: Low molecular weight heparin (LMWH)
- Injection, solution 2,500 units per 0.2 mL
- Injection, solution 5,000 units per 0.2 mL
- Injection, solution 7,500 units per 0.3 mL
- Injection, solution 10,000 units per 0.4 mL
- Injection, solution 10,000 units/mL
- Injection, solution 12,500 units per 0.5 mL
- Injection, solution 15,000 units per 0.6 mL
- Injection, solution 18,000 units per 0.72 mL
- Injection, solution 95,000 units per 3.8 mL
Inhibits reactions that lead to clotting by enhancing the inhibition of factor Xa and thrombin by antithrombin.
Bioavailability is approximately 87%. T max is approximately 4 h.
Vd is 40 to 60 mL/kg.
The half-life is 3 to 5 h.
Special PopulationsRenal Function Impairment
Mean terminal half-life was prolonged to 5.7 h following IV administration to patients with chronic renal insufficiency requiring hemodialysis; greater accumulation can be expected in these patients.
Indications and Usage
Prophylaxis of ischemic complications in unstable angina and non–Q-wave MI when coadministered with aspirin therapy; prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism, in patients undergoing hip replacement surgery, in patients undergoing abdominal surgery who are at risk for thromboembolic complications, or in patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness; extended treatment of symptomatic venous thromboembolism (proximal DVT and/or pulmonary embolism) to reduce recurrence of venous thromboembolism in patients with cancer.
Primary venous thromboembolism prophylaxis in cancer patients; venous thromboembolism prophylaxis in cancer patients with central venous catheters; venous thromboembolism prophylaxis in general or gynecologic surgery.
Active major bleeding; history of heparin-induced thrombocytopenia or heparin-induced thrombocytopenia with thrombosis; as treatment for unstable angina of non–Q-wave MI or prolonged venous thromboembolism prophylaxis in patients undergoing epidural/neuraxial anesthesia; hypersensitivity to dalteparin, heparin, pork products, or to any component of the product.
Dosage and AdministrationUnstable Angina/Non–Q-Wave MI
Subcutaneous 120 units/kg (max, 10,000 units) every 12 h with aspirin (75 to 165 mg/day, unless contraindicated) therapy. Continue treatment until patient is clinically stabilized, usually 5 to 8 days.DVT Prophylaxis (Hip Replacement Surgery)
Subcutaneous If started postoperatively, 2,500 units within 4 to 8 h after surgery, followed by 5,000 units/day; if started preoperatively on day of surgery, 2,500 units within 2 h before surgery, followed by 2,500 units 4 to 8 h after surgery and continued at 5,000 units/day; if started preoperatively on the evening before surgery, 5,000 units 10 to 14 h before surgery, followed by 5,000 units 4 to 8 h after surgery and continued at 5,000 units/day. Usual duration is 5 to 10 days postoperatively.DVT Prophylaxis (Abdominal Surgery)
Subcutaneous 2,500 units starting 1 to 2 h before surgery and continuing once daily. In patients undergoing abdominal surgery with a high risk of complications (eg, malignant disorder), recommended dose is 5,000 units the evening before surgery, then once daily. Alternatively, in patients with malignancy, dalteparin 2,500 units can be administered 1 to 2 h before surgery followed by 2,500 units 12 h later, and then 5,000 units once daily. Usual duration is 5 to 10 days postoperatively.DVT Prophylaxis (Medical Patients With Severely Restricted Mobility During Acute Illness)
Subcutaneous 5,000 units/day for 12 to 14 days.Extended Treatment of Symptomatic Venous Thromboembolism in Cancer Patients
Subcutaneous For the first 30 days of treatment, give 200 units/kg once daily (max, 18,000 units/day). For months 2 to 6, administer 150 units/kg once daily (max, 18,000 units/day).Dose reductions for thrombocytopenia
In patients with platelet counts between 50,000 and 100,000/mm 3 , reduce the daily dose by 2,500 units until platelet count recovers to at least 100,000/mm 3 . In patients who experience platelet counts below 50,000/mm 3 , discontinue dalteparin until platelet count recovers to above 50,000/mm 3 .Dose reductions for renal impairment
In patients with severe renal impairment (CrCl less than 30 mL/min), monitor for anti–factor Xa levels to determine dalteparin dose. Target anti–factor Xa range is 0.5 to 1.5 units/mL. Sampling should be performed 4 to 6 h after dosing and only after 3 to 4 doses have been given.
- For deep subcutaneous injection. Do not administer by IM injection.
- Vary injection site daily. Dalteparin may be injected in a U-shape area around the navel, the upper outer side of the thigh, or the upper outer quadrangle of the buttock.
- Do not mix with other injections or infusions until compatibility is determined.
Store between 68° and 77°F. After first penetration of the rubber stopper, store the multidose vial at room temperature for up to 2 wk. Discard any unused solution in multidose vial after 2 wk.
Drug InteractionsAnticoagulants (eg, warfarin), platelet inhibitors (eg, clopidogrel, dipyridamole, NSAIDs, salicylates, ticlopidine), thrombolytic agents (eg, alteplase, tenecteplase)
Increased risk of bleeding. Use with caution.Antithrombin
The risk of severe bleeding may be increased. Close clinical and laboratory monitoring (APTT and/or anti-Xa) is indicated during coadministration of dalteparin and antithrombin. Adjust the dose of dalteparin accordingly. Reduced doses of dalteparin are recommended when coadministered with antithrombin III.Palifermin
Palifermin plasma concentrations and pharmacologic effects may be increased. Avoid coadministration.Rivaroxaban, thrombin inhibitors (eg, dabigatran, desirudin)
The risk of severe bleeding may be increased. Avoid coadministration.SSRIs (eg, fluoxetine)
The risk of severe bleeding may be increased. Carefully monitor the coagulation status of the patient and observe for bleeding. Adjust therapy as needed.
Alopecia, skin necrosis (postmarketing).
Any bleeding event (14%); thrombocytopenia (11%); major bleeding events (6%).
Allergic reactions, including pruritus, rash, fever, injection-site reaction, or bullous eruption; anaphylactoid reactions.
ALT elevation (14%); AST elevation (12%).
Injection-site pain (12%); injection-site hematoma (7%); wound hematoma (3%).
Epidural or spinal hematoma (postmarketing).
Spinal/epidural hematoma, which can result in long-term or permanent paralysis, may occur in patients receiving neuraxial anesthesia or spinal puncture who are anticoagulated with LMWHs or heparinoids. Other risk factors include indwelling epidural catheters, repeated/traumatic epidural/spinal puncture, history of spinal deformity or spinal surgery, or use of other drugs affecting hemostasis (eg, NSAIDs, platelet inhibitors, anticoagulants).
Periodic routine CBC, including platelet count, blood chemistry, and stool occult blood tests, is recommended; anticoagulant effect can be monitored by using anti–factor Xa in patients with severe renal impairment or if abnormal coagulation parameters or bleeding occur. Monitor patients frequently for signs and symptoms of neurologic impairment. Closely monitor thrombocytopenia of any degree.
Category B .
Safety and efficacy not established.
Careful attention to dosing intervals and concomitant medications (especially antiplatelet medications) is advised, particularly in elderly patients weighing less than 45 kg and those with decreased renal function.
Use with caution in patients with severe renal impairment.
The multiple-dose vial of dalteparin contains benzyl alcohol as a preservative, which has been associated with fatal “gasping syndrome” in premature infants.
Heparin-induced thrombocytopenia can occur. Cases of thrombocytopenia with thrombosis, amputation, and death have been observed.
- Inform patients who have had neuraxial anesthesia or spinal puncture, especially if they are taking concomitant NSAIDs, platelet inhibitors, or other anticoagulants, that they should watch for signs and symptoms of spinal or epidural hematoma such as tingling, numbness (especially in the lower limbs), and muscular weakness, and to contact their health care provider immediately if they occur.
- Advise patients that the use of aspirin and other NSAIDs may enhance the risk of hemorrhage.
- Instruct patient to report any signs of bleeding or bruising, signs of thrombocytopenia (eg, a rash of dark spots under the skin), or black, bloody, or tarry stools immediately.
- If patient has home therapy, teach patient or family member proper subcutaneous injection technique.
- Inform patients that it may take them longer than usual to stop bleeding and that they may bruise and/or bleed more easily when they are treated with dalteparin. Caution patient to take safety precautions to prevent cuts and bruising (eg, use electric razor, soft toothbrush, and handrails).
- Advise patients to inform their health care providers and dentists that they are taking dalteparin or any other product known to affect bleeding before any surgery is scheduled or before any new drug is taken.
Copyright © 2009 Wolters Kluwer Health.